	US 11,938,143 B2
	Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
Santhosh Vadivelu, Wellesley, MA (US)
Assigned to AkiraBio, Inc., Wellesley, MA (US)
Filed by AkiraBio, Inc., Wellesley, MA (US)
Filed on Oct. 19, 2022, as Appl. No. 17/969,192.
Claims priority of provisional application 63/257,541, filed on Oct. 19, 2021.
Prior Publication US 2023/0122664 A1, Apr. 20, 2023
Int. Cl. A61K 31/7068 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/53 (2006.01); A61K 35/28 (2015.01); A61P 7/00 (2006.01)

CPC A61K 31/7068 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/4825 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 31/53 (2013.01); A61K 35/28 (2013.01); A61P 7/00 (2018.01)]

20 Claims

1. A method for treating a hematological disorder in a subject, the method comprising:

orally administering a first therapeutic agent to the subject in a regimen for treating the hematological disorder,

wherein the first therapeutic agent is 5-aza-4′-thio-2′-deoxycytidine, or a pharmaceutically acceptable salt thereof,

wherein the regimen for treating the hematological disorder does not include administering a cytidine deaminase inhibitor to the subject, and

wherein the hematological disorder is sickle cell disease or thalassemia.